CD134 (OX40) Monoclonal Antibody (OX-86), Super Bright™ 436, eBioscience™, Invitrogen™

Description

• Description: The OX-86 monoclonal antibody reacts with mouse CD134, also known as OX40
• A member of the TNF receptor superfamily, CD134 is a 50 kDa type I membrane glycoprotein expressed by activated mouse T lymphocytes
• Rat CD134 was initially identified as an activation marker only on activated CD4+ T cells
• In contrast, mouse CD134 is expressed by both activated CD4+ and CD8+ T cells
• The interaction of CD134 with CD252 (OX40 ligand) has been implicated in T cell-dependent humoral responses, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool, and regulation of tolerance in the CD4+ T cell compartment
• Applications Reported: This OX-86 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This OX-86 antibody has been tested by flow cytometric analysis of stimulated mouse splenocytes
• This can be used at less than or equal to 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Super Bright 436 can be excited with the violet laser line (405 nm) and emits at 436 nm
• We recommend using a 450/50 bandpass filter, or equivalent
• Please make sure that your instrument is capable of detecting this fluorochrome
• OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system
• When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents
• OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer
• They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.